Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.40 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL29379109 | 1.00 | PDE4A (0.76) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL5805996 | 0.98 | PDE4A (0.79) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL28069153 | 0.98 | PDE4A (0.79) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL17965938 | 0.96 | PDE4A (0.76) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL25413097 | 0.89 | PDE4A (0.95) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL29367310 | 0.89 | PDE4A (0.95) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL29448461 | 0.89 | PDE4A (0.95) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL15703361 | 0.89 | PDE4A (0.95) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL6535948 | 0.89 | PDE4A (0.95) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL543242 | 0.89 | PDE4A (0.95) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080075674-A1 | chewable tablets having flavors and antitussive agents selected from dextromethorphan, noscapine, ethyl morphine, codeine, menthol, zinc gluconate glycine, and pectin; sustained release of flavors | DUPRATT BRIAN D | 2008-03-27 | — | — | US | claimed |
| US-20230241165-A1 | MANNOSE-BINDING LECTIN FOR TREATMENT OR PROPHYLAXIS OF INFECTIOUS DISEASES | ESS HOLDING GMBH (AT) | 2023-08-03 | — | — | US | disclosed |
| EP-4146245-A1 | MANNOSE-BINDING LECTIN FOR TREATMENT OR PROPHYLAXIS OF INFECTIOUS DISEASES | ESS Holding GmbH (AT) | 2023-03-15 | — | — | EP | disclosed |
| WO-2021222965-A1 | MANNOSE-BINDING LECTIN FOR TREATMENT OR PROPHYLAXIS OF INFECTIOUS DISEASES | ESS HOLDING GMBH (AT) | 2021-11-11 | — | — | WO | disclosed |
| US-20170087056-A1 | Blister Cards Promoting Intuitive Dosing | PROCTER & GAMBLE (US) | 2017-03-30 | — | — | US | disclosed |
| US-9526673-B2 | Blister cards promoting intuitive dosing | THE PROCTER & GAMBLE COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9445970-B2 | Blister cards promoting intuitive dosing | THE PROCTER & GAMBLE COMPANY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160193112-A1 | Blister Cards Promoting Intuitive Dosing | PROCTER & GAMBLE (US) | 2016-07-07 | — | — | US | disclosed |
| US-9314402-B2 | Blister cards promoting intuitive dosing | THE PROCTER & GAMBLE COMPANY (US) | 2016-04-19 | — | — | US | disclosed |
| EP-2651365-B1 | BLISTER CARDS PROMOTING INTUITIVE DOSING | PROCTER & GAMBLE (US) | 2016-02-24 | — | — | EP | disclosed |
| US-20060068038-A1 | Mineral additives for improved processing of compositions containing vitamin E and saw palmetto | PROETHIC LABORATORIES, L.L.C. (US) | 2006-03-30 | — | — | US | disclosed |
| US-20050191369-A1 | Compositions comprising vitamin E and saw palmetto | PROETHIC LABORATORIES, L.L.C. (US) | 2005-09-01 | — | — | US | disclosed |
| US-20030175332-A1 | Methods of preventing or treating diseases and conditions using complex carbohydrates | DERMAL RESEARCH LABORATORIES, INC. | 2003-09-18 | — | — | US | disclosed |
| EP-1311276-A1 | METHODS OF PREVENTING OR TREATING DISEASES AND CONDITIONS USING COMPLEX CARBOHYDRATES | Dermal Research Laboratories, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-0987021-B1 | Slow release compositions containing a zinc compound and vitamin C derivatives | GODFREY JOHN C (US) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002009728-A1 | METHODS OF PREVENTING OR TREATING DISEASES AND CONDITIONS USING COMPLEX CARBOHYDRATES | DERMAL RESEARCH LABORATORIES, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| EP-1165097-A2 | A PHARMACEUTICAL COMPOSITION OF COMPLEX CARBOHYDRATES AND ESSENTIAL OILS AND METHODS OF USING THE SAME | Dermal Research Laboratories, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6316008-B1 | Combination of zinc ions and vitamin C and method of making | GODFREY JOHN C (US) | 2001-11-13 | — | — | US | disclosed |
| WO-2000044367-A2 | A PHARMACEUTICAL COMPOSITION OF COMPLEX CARBOHYDRATES AND ESSENTIAL OILS AND METHODS OF USING THE SAME | DERMAL RESEARCH LABORATORIES, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-0987021-A1 | Slow release compositions containing a zinc compound and vitamin C derivatives | Godfrey, John C. (US) | 2000-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050191369-A1 | Compositions comprising vitamin E and saw palmetto | TTPA, GPX4, CYP24A1 | PDE4A 4317/4885LMNA 1142/4885USP2 1775/4885 |
| US-20060068038-A1 | Mineral additives for improved processing of compositions containing vitamin E and saw palmetto | SOST, TTPA, CYP24A1 | PDE4A 4066/4885LMNA 1208/4885USP2 3050/4885 |
| US-20230241165-A1 | MANNOSE-BINDING LECTIN FOR TREATMENT OR PROPHYLAXIS OF INFECTIOUS DISEASES | MASP2, MANBA, MAN2A1 | PDE4A 4623/4885LMNA 465/4885USP2 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.